The company develops and manufactures bulk drug ingredients and finished pharmaceutical formulations, primarily branded generics, for domestic and international markets across various therapeutic areas like diabetes and allergies.
The company operates in a highly competitive generic drug market where low net margins (0.6%) and mediocre ROCE (8.3%) indicate a lack of pricing power or cost advantage. While they hold regulatory approvals, these are standard requirements rather than durable competitive moats, as evidenced by the revenue decline in 2025 due to stiff international competition.
Management has prioritized maintaining a high debt-to-equity ratio (nearly 2.0) while paying out dividends despite very thin profit margins and low returns on equity. Reinvestment in R&D is modest at approximately 1-1.4% of turnover, which may be insufficient to build a high-value proprietary pipeline.
The company's thin interest coverage of 1.35 finally buckled under the weight of its nearly 2.0 debt-to-equity ratio as global interest rates remained elevated. With net margins of only 0.6%, a minor uptick in raw material costs or a further revenue decline—similar to the one observed in 2025—evaporated all remaining profit. The business became a 'zombie' entity, unable to fund the R&D necessary to compete in generics, eventually leading to a liquidity crisis where receivables from subsidiaries proved unrecoverable, forcing a fire sale or restructuring that wiped out equity holders.
RichFakir rates Bal Pharma Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Bal Pharma Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Bal Pharma Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Bal Pharma Ltd's fair value is about ₹48 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →